Pancreatic cancer trial aims to supercharge immune system before surgery

NCT ID NCT06048484

Recruiting now Disease control Sponsor: Gulam Manji Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding drugs that block the tumor's immune-evasion pathways to standard radiation and immunotherapy can boost the body's immune attack on pancreatic cancer before surgery. About 60 patients with advanced pancreatic cancer who are candidates for surgery will receive different combinations of these drugs along with radiation. The main goal is to see if these combos increase cancer-fighting immune cells in the tumor and improve surgical outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zimberelimab, Quemliclustat, Etrumadenant, modified FOLFIRINOX, and stereotactic body radiotherapy
What this could lead to: If successful, this could improve immune attack on pancreatic tumors, potentially increasing surgical success and long-term control.
What could go wrong: This is an early phase 2 trial with only 60 participants. The added drugs may cause more side effects, and the immune response may not translate to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Northwell Health R.J. Zuckerberg Cancer Center
RECRUITING

Lake Success, New York, 11042, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Pennsylvania, Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.